Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 405 articles:
HTML format
Text format



Single Articles


    October 2019
  1. IWASA T, Tsurutani J, Watanabe S, Kato R, et al
    Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    BMC Cancer. 2019;19:962.
    PubMed     Text format     Abstract available


  2. ZHANG JJ, Zhang WC, An CX, Li XM, et al
    Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer.
    BMC Cancer. 2019;19:956.
    PubMed     Text format     Abstract available


  3. SUROV A, Meyer HJ, Wienke A
    Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.
    BMC Cancer. 2019;19:955.
    PubMed     Text format     Abstract available


  4. ZHOU Y, Li Y, Mao F, Zhang J, et al
    Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer.
    BMC Cancer. 2019;19:939.
    PubMed     Text format     Abstract available


    September 2019
  5. MCCULLOUGH LE, Collin LJ, Conway K, White AJ, et al
    Reproductive characteristics are associated with gene-specific promoter methylation status in breast cancer.
    BMC Cancer. 2019;19:926.
    PubMed     Text format     Abstract available


  6. ZHANG J, Liu Y, Zang M, Zhu S, et al
    Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer.
    BMC Cancer. 2019;19:921.
    PubMed     Text format     Abstract available


  7. BORM KJ, Schonknecht C, Nestler A, Oechsner M, et al
    Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients.
    BMC Cancer. 2019;19:907.
    PubMed     Text format     Abstract available


  8. DANIELS B, Kiely BE, Tang M, Tervonen H, et al
    Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
    BMC Cancer. 2019;19:909.
    PubMed     Text format     Abstract available


  9. SCHMID S, Klingbiel D, Aebi S, Goldhirsch A, et al
    Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
    BMC Cancer. 2019;19:902.
    PubMed     Text format     Abstract available


  10. XIAO B, Chen D, Zhou Q, Hang J, et al
    Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
    BMC Cancer. 2019;19:891.
    PubMed     Text format     Abstract available


  11. BAYARMAA B, Wu Z, Peng J, Wang Y, et al
    Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:877.
    PubMed     Text format     Abstract available


  12. KRZYZANOWSKA MK, Julian JA, Powis M, Howell D, et al
    Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    BMC Cancer. 2019;19:884.
    PubMed     Text format     Abstract available


  13. MCQUERRY JA, Jenkins DF, Yost SE, Zhang Y, et al
    Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    BMC Cancer. 2019;19:881.
    PubMed     Text format     Abstract available


  14. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Text format     Abstract available


    August 2019
  15. KIM WH, Kim HJ, Kim SH, Jung JH, et al
    Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study.
    BMC Cancer. 2019;19:859.
    PubMed     Text format     Abstract available


  16. CHAE BJ, Lee J, Lee SK, Shin HJ, et al
    Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study.
    BMC Cancer. 2019;19:839.
    PubMed     Text format     Abstract available


  17. WONDIMAGEGNEHU A, Abebe W, Abraha A, Teferra S, et al
    Depression and social support among breast cancer patients in Addis Ababa, Ethiopia.
    BMC Cancer. 2019;19:836.
    PubMed     Text format     Abstract available


  18. ZENG L, Deng X, Zhong J, Yuan L, et al
    Prognostic value of biomarkers EpCAM and alphaB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.
    BMC Cancer. 2019;19:831.
    PubMed     Text format     Abstract available


  19. WAHABI K, Perwez A, Kamarudheen S, Bhat ZI, et al
    Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
    BMC Cancer. 2019;19:820.
    PubMed     Text format     Abstract available


  20. NUR U, El Reda D, Hashim D, Weiderpass E, et al
    A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women's lifestyle and health cohort.
    BMC Cancer. 2019;19:807.
    PubMed     Text format     Abstract available


  21. MA H, Malone KE, McDonald JA, Marchbanks PA, et al
    Pre-diagnosis alcohol consumption and mortality risk among black women and white women with invasive breast cancer.
    BMC Cancer. 2019;19:800.
    PubMed     Text format     Abstract available


  22. SEPAHI I, Faust U, Sturm M, Bosse K, et al
    Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
    BMC Cancer. 2019;19:787.
    PubMed     Text format     Abstract available


  23. GOMES CP, Nobrega-Pereira S, Domingues-Silva B, Rebelo K, et al
    An antisense transcript mediates MALAT1 response in human breast cancer.
    BMC Cancer. 2019;19:771.
    PubMed     Text format     Abstract available


    July 2019
  24. BARRENO L, Caceres S, Alonso-Diez A, Vicente-Montana A, et al
    Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines.
    BMC Cancer. 2019;19:750.
    PubMed     Text format     Abstract available


  25. LATTANZIO R, Iezzi M, Sala G, Tinari N, et al
    PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    BMC Cancer. 2019;19:747.
    PubMed     Text format     Abstract available


  26. KOCIK J, Pajaczek M, Kryczka T
    Worse survival in breast cancer in elderly may not be due to underutilization of medical procedures as observed upon changing healthcare system in Poland.
    BMC Cancer. 2019;19:749.
    PubMed     Text format     Abstract available


  27. WANG H, Tan Z, Hu H, Liu H, et al
    microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1.
    BMC Cancer. 2019;19:738.
    PubMed     Text format     Abstract available


  28. CARAYOL M, Ninot G, Senesse P, Bleuse JP, et al
    Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.
    BMC Cancer. 2019;19:737.
    PubMed     Text format     Abstract available


  29. TIAINEN L, Korhonen EA, Leppanen VM, Luukkaala T, et al
    High baseline Tie1 level predicts poor survival in metastatic breast cancer.
    BMC Cancer. 2019;19:732.
    PubMed     Text format     Abstract available


  30. QIU Y, Wang L, Zhong X, Li L, et al
    A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer.
    BMC Cancer. 2019;19:729.
    PubMed     Text format     Abstract available


  31. ESPARZA-LOPEZ J, Alvarado-Munoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, et al
    Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-kappaB pathways.
    BMC Cancer. 2019;19:728.
    PubMed     Text format     Abstract available


  32. ZAYAS-VILLANUEVA OA, Campos-Acevedo LD, Lugo-Trampe JJ, Hernandez-Barajas D, et al
    Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    BMC Cancer. 2019;19:722.
    PubMed     Text format     Abstract available


  33. CASEY MC, Prakash A, Holian E, McGuire A, et al
    Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
    BMC Cancer. 2019;19:712.
    PubMed     Text format     Abstract available


  34. LAIBLE M, Hartmann K, Gurtler C, Anzeneder T, et al
    Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    BMC Cancer. 2019;19:694.
    PubMed     Text format     Abstract available


  35. DANZINGER S, Tan YY, Rudas M, Kastner MT, et al
    Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    BMC Cancer. 2019;19:695.
    PubMed     Text format     Abstract available


  36. MARKL B, Kazik M, Harbeck N, Jakubowicz E, et al
    Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
    BMC Cancer. 2019;19:692.
    PubMed     Text format     Abstract available


  37. LIM SM, Han Y, Kim SI, Park HS, et al
    Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study.
    BMC Cancer. 2019;19:669.
    PubMed     Text format     Abstract available


  38. MARTIN-PARDILLOS A, Valls Chiva A, Bande Vargas G, Hurtado Blanco P, et al
    The role of clonal communication and heterogeneity in breast cancer.
    BMC Cancer. 2019;19:666.
    PubMed     Text format     Abstract available


  39. MCBRIDE ML, Groome PA, Decker K, Kendell C, et al
    Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.
    BMC Cancer. 2019;19:659.
    PubMed     Text format     Abstract available


  40. SINGLETON A, Partridge SR, Raeside R, Regimbal M, et al
    A text message intervention to support women's physical and mental health after breast cancer treatments (EMPOWER-SMS): a randomised controlled trial protocol.
    BMC Cancer. 2019;19:660.
    PubMed     Text format     Abstract available


  41. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial.
    BMC Cancer. 2019;19:653.
    PubMed     Text format     Abstract available


    June 2019
  42. HANNAFON BN, Cai A, Calloway CL, Xu YF, et al
    miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.
    BMC Cancer. 2019;19:642.
    PubMed     Text format     Abstract available


  43. CHEN JH, Huang WC, Bamodu OA, Chang PM, et al
    Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    BMC Cancer. 2019;19:634.
    PubMed     Text format     Abstract available


  44. MORAN O, Eisen A, Demsky R, Blackmore K, et al
    Predictors of mammographic density among women with a strong family history of breast cancer.
    BMC Cancer. 2019;19:631.
    PubMed     Text format     Abstract available


  45. MAJID S, Ryden L, Manjer J
    Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
    BMC Cancer. 2019;19:626.
    PubMed     Text format     Abstract available


  46. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
    BMC Cancer. 2019;19:615.
    PubMed     Text format     Abstract available


  47. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:620.
    PubMed     Text format     Abstract available


  48. WALLWIENER M, Nabieva N, Feisst M, Fehm T, et al
    Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
    BMC Cancer. 2019;19:611.
    PubMed     Text format     Abstract available


  49. DIHGE L, Ohlsson M, Eden P, Bendahl PO, et al
    Artificial neural network models to predict nodal status in clinically node-negative breast cancer.
    BMC Cancer. 2019;19:610.
    PubMed     Text format     Abstract available


  50. GEBREHIWOT AG, Melka DS, Kassaye YM, Gemechu T, et al
    Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    BMC Cancer. 2019;19:588.
    PubMed     Text format     Abstract available


  51. WANG C, Xu C, Niu R, Hu G, et al
    MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.
    BMC Cancer. 2019;19:577.
    PubMed     Text format     Abstract available


  52. KUMLER I, Balslev E, Stenvang J, Brunner N, et al
    Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
    BMC Cancer. 2019;19:573.
    PubMed     Text format     Abstract available


  53. SCHWARTZBERG L, McIntyre K, Wilks S, Puhalla S, et al
    Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    BMC Cancer. 2019;19:578.
    PubMed     Text format     Abstract available


  54. ZHANG J, Li K, Zhang Y, Lu R, et al
    Deletion of sorting nexin 27 suppresses proliferation in highly aggressive breast cancer MDA-MB-231 cells in vitro and in vivo.
    BMC Cancer. 2019;19:555.
    PubMed     Text format     Abstract available


  55. LALL K, Lepamets M, Palover M, Esko T, et al
    Polygenic prediction of breast cancer: comparison of genetic predictors and implications for risk stratification.
    BMC Cancer. 2019;19:557.
    PubMed     Text format     Abstract available


  56. BUSTAMANTE EDUARDO M, Popovici V, Imboden S, Aebi S, et al
    Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    BMC Cancer. 2019;19:549.
    PubMed     Text format     Abstract available


  57. YANG Y, Wang Y, Deng H, Tan C, et al
    Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    BMC Cancer. 2019;19:541.
    PubMed     Text format     Abstract available


  58. CHANG VC, Cotterchio M, Khoo E
    Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:543.
    PubMed     Text format     Abstract available


    May 2019
  59. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:517.
    PubMed     Text format     Abstract available


  60. HOLLECZEK B, Stegmaier C, Radosa JC, Solomayer EF, et al
    Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany.
    BMC Cancer. 2019;19:520.
    PubMed     Text format     Abstract available


  61. KIKUCHI-KOIKE R, Nagasaka K, Tsuda H, Ishii Y, et al
    Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
    BMC Cancer. 2019;19:521.
    PubMed     Text format     Abstract available


  62. PLAZA-DIAZ J, Alvarez-Mercado AI, Ruiz-Marin CM, Reina-Perez I, et al
    Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
    BMC Cancer. 2019;19:495.
    PubMed     Text format     Abstract available


  63. RUTKOVSKY AC, Yeh ES, Guest ST, Findlay VJ, et al
    Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    BMC Cancer. 2019;19:491.
    PubMed     Text format     Abstract available


  64. OLSSON MOLLER U, Beck I, Ryden L, Malmstrom M, et al
    A comprehensive approach to rehabilitation interventions following breast cancer treatment - a systematic review of systematic reviews.
    BMC Cancer. 2019;19:472.
    PubMed     Text format     Abstract available


  65. PEISL S, Zimmermann S, Camey B, Betticher D, et al
    Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg.
    BMC Cancer. 2019;19:469.
    PubMed     Text format     Abstract available


  66. YANG X, Zhang K, Zhang C, Peng R, et al
    Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    BMC Cancer. 2019;19:465.
    PubMed     Text format     Abstract available


  67. WANG K, Wang G, Huang S, Luo A, et al
    Association between TIMP-2 gene polymorphism and breast cancer in Han Chinese women.
    BMC Cancer. 2019;19:446.
    PubMed     Text format     Abstract available


  68. ZHENG A, Zhang L, Song X, Wang Y, et al
    Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients.
    BMC Cancer. 2019;19:451.
    PubMed     Text format     Abstract available


  69. YI Z, Ma F, Liu B, Guan X, et al
    Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    BMC Cancer. 2019;19:442.
    PubMed     Text format     Abstract available


  70. MCANENA P, Tanriverdi K, Curran C, Gilligan K, et al
    Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    BMC Cancer. 2019;19:436.
    PubMed     Text format     Abstract available


  71. VALE DB, Filho CC, Shinzato JY, Spreafico FS, et al
    Downstaging in opportunistic breast cancer screening in Brazil: a temporal trend analysis.
    BMC Cancer. 2019;19:432.
    PubMed     Text format     Abstract available


  72. ARAS S, Maroun MC, Song Y, Bandyopadhyay S, et al
    Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis.
    BMC Cancer. 2019;19:411.
    PubMed     Text format     Abstract available


    April 2019
  73. ZAKRZEWSKI F, Gieldon L, Rump A, Seifert M, et al
    Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    BMC Cancer. 2019;19:396.
    PubMed     Text format     Abstract available


  74. DERESSA BT, Cihoric N, Badra EV, Tsikkinis A, et al
    Breast cancer care in northern Ethiopia - cross-sectional analysis.
    BMC Cancer. 2019;19:393.
    PubMed     Text format     Abstract available


  75. LEE J, Lee EH, Park HY, Kim WW, et al
    Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
    BMC Cancer. 2019;19:388.
    PubMed     Text format     Abstract available


  76. ZHAO Y, Luo H, Zhang X, Bianba T, et al
    Clinicopathological characteristics and health care for Tibetan women with breast cancer: a cross-sectional survey.
    BMC Cancer. 2019;19:380.
    PubMed     Text format     Abstract available


  77. LU L, Huang H, Zhou J, Ma W, et al
    BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
    BMC Cancer. 2019;19:387.
    PubMed     Text format     Abstract available


  78. SALERNO EA, Rowland K, Kramer AF, McAuley E, et al
    Acute aerobic exercise effects on cognitive function in breast cancer survivors: a randomized crossover trial.
    BMC Cancer. 2019;19:371.
    PubMed     Text format     Abstract available


  79. CHAO X, Chen K, Zeng J, Bi Z, et al
    Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:372.
    PubMed     Text format     Abstract available


  80. RUFFALO M, Bar-Joseph Z
    Protein interaction disruption in cancer.
    BMC Cancer. 2019;19:370.
    PubMed     Text format     Abstract available


  81. BRUNORO GVF, Carvalho PC, Barbosa VC, Pagnoncelli D, et al
    Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow.
    BMC Cancer. 2019;19:365.
    PubMed     Text format     Abstract available


  82. MCCLEMENTS L, Annett S, Yakkundi A, O'Rourke M, et al
    FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    BMC Cancer. 2019;19:351.
    PubMed     Text format     Abstract available


  83. GASS J, Mitchell S, Hanna M
    How do breast cancer surgery scars impact survivorship? Findings from a nationwide survey in the United States.
    BMC Cancer. 2019;19:342.
    PubMed     Text format     Abstract available


  84. ZHANG W, Jin ZQ, Baikpour M, Li JM, et al
    Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.
    BMC Cancer. 2019;19:345.
    PubMed     Text format     Abstract available


  85. HEUSER C, Diekmann A, Kowalski C, Enders A, et al
    Health literacy and patient participation in multidisciplinary tumor conferences in breast cancer care: a multilevel modeling approach.
    BMC Cancer. 2019;19:330.
    PubMed     Text format     Abstract available


  86. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Text format     Abstract available


  87. WU L, Wu D, Ning J, Liu W, et al
    Changes of N6-methyladenosine modulators promote breast cancer progression.
    BMC Cancer. 2019;19:326.
    PubMed     Text format     Abstract available


  88. CAMPOY EM, Branham MT, Mayorga LS, Roque M, et al
    Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    BMC Cancer. 2019;19:328.
    PubMed     Text format     Abstract available


  89. SHAHI RB, De Brakeleer S, Caljon B, Pauwels I, et al
    Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    BMC Cancer. 2019;19:313.
    PubMed     Text format     Abstract available


  90. FERRARO DA, Patella F, Zanivan S, Donato C, et al
    Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells.
    BMC Cancer. 2019;19:312.
    PubMed     Text format     Abstract available


  91. RAIHAN J, Ahmad U, Yong YK, Eshak Z, et al
    Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines.
    BMC Cancer. 2019;19:315.
    PubMed     Text format     Abstract available


  92. KLEIN J, Tran W, Watkins E, Vesprini D, et al
    Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.
    BMC Cancer. 2019;19:306.
    PubMed     Text format     Abstract available


  93. CAMPBELL EJ, Dachs GU, Morrin HR, Davey VC, et al
    Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.
    BMC Cancer. 2019;19:307.
    PubMed     Text format     Abstract available


  94. MULLAN PB, Bingham V, Haddock P, Irwin GW, et al
    NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
    BMC Cancer. 2019;19:236.
    PubMed     Text format     Abstract available


    March 2019
  95. CAPERCHIONE CM, Sabiston CM, Stolp S, Bottorff JL, et al
    A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
    BMC Cancer. 2019;19:272.
    PubMed     Text format     Abstract available


  96. MENDIETA I, Nunez-Anita RE, Nava-Villalba M, Zambrano-Estrada X, et al
    Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
    BMC Cancer. 2019;19:261.
    PubMed     Text format     Abstract available


  97. ABDULRASHID K, AlHussaini N, Ahmed W, Thalib L, et al
    Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
    BMC Cancer. 2019;19:256.
    PubMed     Text format     Abstract available


  98. KIM MH, Kim DW, Park S, Kim JH, et al
    Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study.
    BMC Cancer. 2019;19:251.
    PubMed     Text format     Abstract available


  99. ATTULURI AK, Serkad CPV, Gunda A, Ramkumar C, et al
    Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
    BMC Cancer. 2019;19:249.
    PubMed     Text format     Abstract available


  100. SMELAND HY, Lu N, Karlsen TV, Salvesen G, et al
    Stromal integrin alpha11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.
    BMC Cancer. 2019;19:234.
    PubMed     Text format     Abstract available


  101. YADAV S, Hartkop S, Cardenas PY, Ladkany R, et al
    Utilization of a breast cancer risk assessment tool by internal medicine residents in a primary care clinic: impact of an educational program.
    BMC Cancer. 2019;19:228.
    PubMed     Text format     Abstract available


  102. PHUNG MT, Tin Tin S, Elwood JM
    Prognostic models for breast cancer: a systematic review.
    BMC Cancer. 2019;19:230.
    PubMed     Text format     Abstract available


  103. RAMIREZ AB, Bhat R, Sahay D, De Angelis C, et al
    Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    BMC Cancer. 2019;19:220.
    PubMed     Text format     Abstract available


  104. DE ALMEIDA BP, Apolonio JD, Binnie A, Castelo-Branco P, et al
    Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
    BMC Cancer. 2019;19:219.
    PubMed     Text format     Abstract available


  105. CHAI D, Li K, Du H, Yang S, et al
    beta2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().
    BMC Cancer. 2019;19:223.
    PubMed     Text format     Abstract available


  106. CHEN Q, Liu Y, Zhu XL, Feng F, et al
    Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
    BMC Cancer. 2019;19:211.
    PubMed     Text format     Abstract available


  107. XU Y, Kong S, Cheung WY, Bouchard-Fortier A, et al
    Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data.
    BMC Cancer. 2019;19:210.
    PubMed     Text format     Abstract available


  108. KUMAR N, Zhao D, Bhaumik D, Sethi A, et al
    Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    BMC Cancer. 2019;19:215.
    PubMed     Text format     Abstract available


  109. MATOSSIAN MD, Burks HE, Elliott S, Hoang VT, et al
    Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    BMC Cancer. 2019;19:205.
    PubMed     Text format     Abstract available


  110. KATUWAL S, Tapanainen JS, Pukkala E, Kauppila A, et al
    The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women.
    BMC Cancer. 2019;19:199.
    PubMed     Text format     Abstract available


  111. NARANG P, Chen M, Sharma AA, Anderson KS, et al
    The neoepitope landscape of breast cancer: implications for immunotherapy.
    BMC Cancer. 2019;19:200.
    PubMed     Text format     Abstract available


    February 2019
  112. DE LARA S, Nyqvist J, Werner Ronnerman E, Helou K, et al
    The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    BMC Cancer. 2019;19:187.
    PubMed     Text format     Abstract available


  113. LIU H, Wang SH, Chen SC, Chen CY, et al
    Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
    BMC Cancer. 2019;19:176.
    PubMed     Text format     Abstract available


  114. LIU H, Chang X, Shang H, Li F, et al
    Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review.
    BMC Cancer. 2019;19:172.
    PubMed     Text format     Abstract available


  115. RUIZ A, Sebagh M, Saffroy R, Allard MA, et al
    Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.
    BMC Cancer. 2019;19:169.
    PubMed     Text format     Abstract available


  116. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2019;19:152.
    PubMed     Text format     Abstract available


  117. KHAN OF, Cusano E, Raissouni S, Pabia M, et al
    Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
    BMC Cancer. 2019;19:150.
    PubMed     Text format     Abstract available


  118. PETITJEAN A, Smith-Palmer J, Valentine W, Tehard B, et al
    Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    BMC Cancer. 2019;19:140.
    PubMed     Text format     Abstract available


  119. AL-SALAM S, Sudhadevi M, Awwad A, Al Bashir M, et al
    Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:135.
    PubMed     Text format     Abstract available


  120. WANG L, Liu L, Lou Z, Ding L, et al
    Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
    BMC Cancer. 2019;19:128.
    PubMed     Text format     Abstract available


  121. OGITA M, Sekiguchi K, Akahane K, Ito R, et al
    Damage to sebaceous gland and the efficacy of moisturizer after whole breast radiotherapy: a randomized controlled trial.
    BMC Cancer. 2019;19:125.
    PubMed     Text format     Abstract available


  122. KAHAN Z, Grecea D, Smakal M, Tjulandin S, et al
    Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    BMC Cancer. 2019;19:122.
    PubMed     Text format     Abstract available


  123. KONIG L, Mairinger FD, Hoffmann O, Bittner AK, et al
    Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
    BMC Cancer. 2019;19:120.
    PubMed     Text format     Abstract available


  124. GALLARDO-ALVARADO LN, Tusie-Luna MT, Tussie-Luna MI, Diaz-Chavez J, et al
    Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    BMC Cancer. 2019;19:118.
    PubMed     Text format     Abstract available


    January 2019
  125. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Text format     Abstract available


  126. SCHAFFAR R, Belot A, Rachet B, Woods L, et al
    On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.
    BMC Cancer. 2019;19:107.
    PubMed     Text format     Abstract available


  127. MUMIN NH, Drobnitzky N, Patel A, Lourenco LM, et al
    Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    BMC Cancer. 2019;19:102.
    PubMed     Text format     Abstract available


  128. SUAREZ-KELLY LP, Pasley WH, Clayton EJ, Povoski SP, et al
    Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial.
    BMC Cancer. 2019;19:99.
    PubMed     Text format     Abstract available


  129. ZHAO ZM, Yost SE, Hutchinson KE, Li SM, et al
    CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    BMC Cancer. 2019;19:96.
    PubMed     Text format     Abstract available


  130. KOTSAKIS A, Ardavanis A, Koumakis G, Samantas E, et al
    Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    BMC Cancer. 2019;19:88.
    PubMed     Text format     Abstract available


  131. EBNER F, Wockel A, Schwentner L, Blettner M, et al
    Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
    BMC Cancer. 2019;19:90.
    PubMed     Text format     Abstract available


  132. MEERSON A, Eliraz Y, Yehuda H, Knight B, et al
    Obesity impacts the regulation of miR-10b and its targets in primary breast tumors.
    BMC Cancer. 2019;19:86.
    PubMed     Text format     Abstract available


  133. KIM HK, Lee SH, Kim YJ, Park SE, et al
    Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    BMC Cancer. 2019;19:84.
    PubMed     Text format     Abstract available


  134. MIAH S, Bagu E, Goel R, Ogunbolude Y, et al
    Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
    BMC Cancer. 2019;19:78.
    PubMed     Text format     Abstract available


  135. KANOMATA N, Kurebayashi J, Koike Y, Yamaguchi R, et al
    CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature.
    BMC Cancer. 2019;19:76.
    PubMed     Text format     Abstract available


  136. JEVRIC M, Matic IZ, Krivokuca A, Dordic Crnogorac M, et al
    Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    BMC Cancer. 2019;19:71.
    PubMed     Text format     Abstract available


  137. KIRKHAM AA, Ian Paterson D, Prado CM, Mackey JR, et al
    Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2019;19:75.
    PubMed     Text format     Abstract available


  138. KHODABANDEHLOU N, Mostafaei S, Etemadi A, Ghasemi A, et al
    Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
    BMC Cancer. 2019;19:61.
    PubMed     Text format     Abstract available


  139. BORGQUIST S, Broberg P, Tojjar J, Olsson H, et al
    Statin use and breast cancer survival - a Swedish nationwide study.
    BMC Cancer. 2019;19:54.
    PubMed     Text format     Abstract available


  140. HOUVENAEGHEL G, Lambaudie E, Classe JM, Mazouni C, et al
    Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.
    BMC Cancer. 2019;19:45.
    PubMed     Text format     Abstract available


  141. LOFTERS AK, McBride ML, Li D, Whitehead M, et al
    Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    BMC Cancer. 2019;19:42.
    PubMed     Text format     Abstract available


  142. FRAMARINO-DEI-MALATESTA M, Chiarito A, Bianciardi F, Fiorelli M, et al
    Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    BMC Cancer. 2019;19:36.
    PubMed     Text format     Abstract available


  143. MECHERA R, Soysal SD, Piscuoglio S, Ng CKY, et al
    Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    BMC Cancer. 2019;19:41.
    PubMed     Text format     Abstract available


  144. SUN J, Wang X, Wang C
    Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:31.
    PubMed     Text format     Abstract available


  145. ZHU L, Chen K
    Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis.
    BMC Cancer. 2019;19:26.
    PubMed     Text format     Abstract available


  146. MASELLI-SCHOUERI JH, Affonso-Kaufman FA, de Melo Sette CV, Dos Santos Figueiredo FW, et al
    Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015.
    BMC Cancer. 2019;19:23.
    PubMed     Text format     Abstract available


  147. DE KRUIF JTCM, Visser M, van den Berg MMGA, Derks MJM, et al
    A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.
    BMC Cancer. 2019;19:7.
    PubMed     Text format     Abstract available


  148. COTRIM DP, Ribeiro ARG, Paixao D, de Queiroz Soares DC, et al
    Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    BMC Cancer. 2019;19:4.
    PubMed     Text format     Abstract available


    December 2018
  149. HAMDI Y, Ben Rekaya M, Jingxuan S, Nagara M, et al
    A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci.
    BMC Cancer. 2018;18:1295.
    PubMed     Text format     Abstract available


  150. ZHAO J, Hu C, Wang C, Yu W, et al
    Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
    BMC Cancer. 2018;18:1290.
    PubMed     Text format     Abstract available


  151. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Text format     Abstract available


  152. SSEMMANDA S, Katagirya E, Bukirwa P, Alele D, et al
    Breast diseases histologically diagnosed at a tertiary facility in Uganda (2005-2014).
    BMC Cancer. 2018;18:1285.
    PubMed     Text format     Abstract available


  153. KUEHNEMUTH B, Piseddu I, Wiedemann GM, Lauseker M, et al
    CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    BMC Cancer. 2018;18:1278.
    PubMed     Text format     Abstract available


  154. SCHMID R, Wolf K, Robering JW, Strauss S, et al
    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    BMC Cancer. 2018;18:1273.
    PubMed     Text format     Abstract available


  155. HICKS DG, Buscaglia B, Goda H, McMahon L, et al
    A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
    BMC Cancer. 2018;18:1266.
    PubMed     Text format     Abstract available


  156. FORSARE C, Bak M, Falck AK, Grabau D, et al
    Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.
    BMC Cancer. 2018;18:1226.
    PubMed     Text format     Abstract available


  157. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Text format     Abstract available


  158. ANNUNZIATA MA, Muzzatti B, Bomben F, Flaiban C, et al
    A contribution to the validation of the Italian version of the Body Image Scale (BIS).
    BMC Cancer. 2018;18:1222.
    PubMed     Text format     Abstract available


  159. FARIAS AJ, Wu WH, Du XL
    Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    BMC Cancer. 2018;18:1214.
    PubMed     Text format     Abstract available


  160. LI TY, Chen VC, Yeh DC, Huang SL, et al
    Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis.
    BMC Cancer. 2018;18:1211.
    PubMed     Text format     Abstract available


    November 2018
  161. AL-QASSAB Y, Grassilli S, Brugnoli F, Vezzali F, et al
    Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
    BMC Cancer. 2018;18:1194.
    PubMed     Text format     Abstract available


  162. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
    Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    BMC Cancer. 2018;18:1177.
    PubMed     Text format     Abstract available


  163. CIFU G, Power MC, Shomstein S, Arem H, et al
    Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review.
    BMC Cancer. 2018;18:1163.
    PubMed     Text format     Abstract available


  164. HOUVENAEGHEL G, Cohen M, Raro P, De Troyer J, et al
    Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    BMC Cancer. 2018;18:1153.
    PubMed     Text format     Abstract available


  165. VAN OMMEN-NIJHOF A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, et al
    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    BMC Cancer. 2018;18:1146.
    PubMed     Text format     Abstract available


  166. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Text format     Abstract available


  167. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
    BMC Cancer. 2018;18:1137.
    PubMed     Text format     Abstract available


  168. JEONG J, Seo K, Kim ES
    Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
    BMC Cancer. 2018;18:1109.
    PubMed     Text format     Abstract available


  169. YE FG, Xia C, Ma D, Lin PY, et al
    Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study.
    BMC Cancer. 2018;18:1085.
    PubMed     Text format     Abstract available


  170. DA COSTA AM, Hashim D, Fregnani JHTG, Weiderpass E, et al
    Overall survival and time trends in breast and cervical cancer incidence and mortality in the Regional Health District (RHD) of Barretos, Sao Paulo, Brazil.
    BMC Cancer. 2018;18:1079.
    PubMed     Text format     Abstract available


  171. OBERSTE M, Schaffrath N, Schmidt K, Bloch W, et al
    Protocol for the "Chemobrain in Motion - study" (CIM - study): a randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line
    BMC Cancer. 2018;18:1071.
    PubMed     Text format     Abstract available


  172. RINNERTHALER G, Gampenrieder SP, Petzer A, Burgstaller S, et al
    Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    BMC Cancer. 2018;18:1074.
    PubMed     Text format     Abstract available


  173. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Text format     Abstract available


  174. LEE E, Luo J, Schumacher FR, Van Den Berg D, et al
    Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.
    BMC Cancer. 2018;18:1072.
    PubMed     Text format     Abstract available


    October 2018
  175. GASS P, Lux MP, Rauh C, Hein A, et al
    Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
    BMC Cancer. 2018;18:1051.
    PubMed     Text format     Abstract available


  176. LUHTALA S, Staff S, Kallioniemi A, Tanner M, et al
    Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    BMC Cancer. 2018;18:1045.
    PubMed     Text format     Abstract available


  177. CHEN L, Qi H, Zhang L, Li H, et al
    Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:1038.
    PubMed     Text format     Abstract available


  178. ARCINIEGAS CALLE MC, Sandhu NP, Xia H, Cha SS, et al
    Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    BMC Cancer. 2018;18:1037.
    PubMed     Text format     Abstract available


  179. JOHNSTON SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al
    Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
    BMC Cancer. 2018;18:1027.
    PubMed     Text format     Abstract available


  180. VARGA K, Hollosi A, Paszty K, Hegedus L, et al
    Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2018;18:1029.
    PubMed     Text format     Abstract available


  181. SARINK D, Schock H, Johnson T, Chang-Claude J, et al
    Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
    BMC Cancer. 2018;18:1010.
    PubMed     Text format     Abstract available


  182. SMITH YE, Toomey S, Napoletano S, Kirwan G, et al
    Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    BMC Cancer. 2018;18:1016.
    PubMed     Text format     Abstract available


  183. DALMASSO B, Hatse S, Brouwers B, Laenen A, et al
    Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    BMC Cancer. 2018;18:1014.
    PubMed     Text format     Abstract available


  184. ZHAO Y, Lv F, Chen S, Wang Z, et al
    Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    BMC Cancer. 2018;18:1019.
    PubMed     Text format     Abstract available


  185. YANG Y, Cameron J, Bedi C, Humphris G, et al
    Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer.
    BMC Cancer. 2018;18:1002.
    PubMed     Text format     Abstract available


  186. GEERS J, Wildiers H, Van Calster K, Laenen A, et al
    Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.
    BMC Cancer. 2018;18:994.
    PubMed     Text format     Abstract available


  187. REN JT, Wang MX, Su Y, Tang LY, et al
    Decelerated DNA methylation age predicts poor prognosis of breast cancer.
    BMC Cancer. 2018;18:989.
    PubMed     Text format     Abstract available


  188. ARAKI K, Ito Y, Fukada I, Kobayashi K, et al
    Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    BMC Cancer. 2018;18:982.
    PubMed     Text format     Abstract available


  189. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Text format     Abstract available


  190. LI L, Chang B, Jiang X, Fan X, et al
    Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    BMC Cancer. 2018;18:977.
    PubMed     Text format     Abstract available


  191. EUSTACE AJ, Conlon NT, McDermott MSJ, Browne BC, et al
    Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    BMC Cancer. 2018;18:965.
    PubMed     Text format     Abstract available


  192. GHOREISHI Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, et al
    Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    BMC Cancer. 2018;18:958.
    PubMed     Text format     Abstract available


  193. LEE KH, Kim EY, Yun JS, Park YL, et al
    The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
    BMC Cancer. 2018;18:938.
    PubMed     Text format     Abstract available


    September 2018
  194. INVERNIZZI M, Corti C, Lopez G, Michelotti A, et al
    Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.
    BMC Cancer. 2018;18:935.
    PubMed     Text format     Abstract available


  195. LOPEZ-PINEDA A, Rodriguez-Moran MF, Alvarez-Aguilar C, Fuentes Valle SM, et al
    Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.
    BMC Cancer. 2018;18:933.
    PubMed     Text format     Abstract available


  196. PELIZZARI G, Arpino G, Biganzoli L, Cinieri S, et al
    An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    BMC Cancer. 2018;18:932.
    PubMed     Text format     Abstract available


  197. HOYER J, Vasileiou G, Uebe S, Wunderle M, et al
    Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    BMC Cancer. 2018;18:926.
    PubMed     Text format     Abstract available


  198. WANG RX, Chen S, Huang L, Shao ZM, et al
    Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    BMC Cancer. 2018;18:909.
    PubMed     Text format     Abstract available


  199. JOUALI F, Marchoudi N, Talbi S, Bilal B, et al
    Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    BMC Cancer. 2018;18:900.
    PubMed     Text format     Abstract available


  200. ELWOOD JM, Tawfiq E, TinTin S, Marshall RJ, et al
    Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
    BMC Cancer. 2018;18:897.
    PubMed     Text format     Abstract available


  201. XIONG Z, Deng G, Wang J, Li X, et al
    Could local surgery improve survival in de novo stage IV breast cancer?
    BMC Cancer. 2018;18:885.
    PubMed     Text format     Abstract available


  202. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:876.
    PubMed     Text format     Abstract available


  203. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Text format     Abstract available


  204. SOBOTA A, Ozakinci G
    Determinants of fertility issues experienced by young women diagnosed with breast or gynaecological cancer - a quantitative, cross-cultural study.
    BMC Cancer. 2018;18:874.
    PubMed     Text format     Abstract available


  205. KALINKOVA L, Zmetakova I, Smolkova B, Minarik G, et al
    Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
    BMC Cancer. 2018;18:875.
    PubMed     Text format     Abstract available


  206. FAJKA-BOJA R, Marton A, Toth A, Blazso P, et al
    Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.
    BMC Cancer. 2018;18:872.
    PubMed     Text format     Abstract available


  207. KIRKHAM AA, Paterson DI, Prado CM, Mackey JM, et al
    Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2018;18:864.
    PubMed     Text format     Abstract available


  208. DUIVON M, Perrier J, Joly F, Licaj I, et al
    Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
    BMC Cancer. 2018;18:866.
    PubMed     Text format     Abstract available


  209. NIAZI MKK, Senaras C, Pennell M, Arole V, et al
    Relationship between the Ki67 index and its area based approximation in breast cancer.
    BMC Cancer. 2018;18:867.
    PubMed     Text format     Abstract available


  210. BROEDERS MJM, Allgood P, Duffy SW, Hofvind S, et al
    The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
    BMC Cancer. 2018;18:860.
    PubMed     Text format     Abstract available


    August 2018
  211. HEIL J, Sinn P, Richter H, Pfob A, et al
    RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    BMC Cancer. 2018;18:851.
    PubMed     Text format     Abstract available


  212. HULTSCH S, Kankainen M, Paavolainen L, Kovanen RM, et al
    Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    BMC Cancer. 2018;18:850.
    PubMed     Text format     Abstract available


  213. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Text format     Abstract available


  214. FISH EJ, Irizarry KJ, DeInnocentes P, Ellis CJ, et al
    Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
    BMC Cancer. 2018;18:832.
    PubMed     Text format     Abstract available


  215. MENG M, Xue H, Lei J, Wang Q, et al
    A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.
    BMC Cancer. 2018;18:833.
    PubMed     Text format     Abstract available


  216. VAN BASTELAAR J, Granzier R, van Roozendaal LM, Beets G, et al
    A multi-center, double blind randomized controlled trial evaluating flap fixation after mastectomy using sutures or tissue glue versus conventional closure: protocol for the Seroma reduction After Mastectomy (SAM) trial.
    BMC Cancer. 2018;18:830.
    PubMed     Text format     Abstract available


  217. MENG LL, Wang JL, Xu SP, Zu LD, et al
    Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.
    BMC Cancer. 2018;18:824.
    PubMed     Text format     Abstract available


  218. RICHTER-EHRENSTEIN C, Maak K, Roger S, Ehrenstein T, et al
    Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.
    BMC Cancer. 2018;18:829.
    PubMed     Text format     Abstract available


  219. WANG B, Li D, Rodriguez-Juarez R, Farfus A, et al
    A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    BMC Cancer. 2018;18:817.
    PubMed     Text format     Abstract available


  220. DENARD B, Jiang S, Peng Y, Ye J, et al
    CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
    BMC Cancer. 2018;18:813.
    PubMed     Text format     Abstract available


  221. AIDERUS A, Black MA, Dunbier AK
    Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
    BMC Cancer. 2018;18:805.
    PubMed     Text format     Abstract available


  222. AXELSSON U, Ryden L, Johnsson P, Eden P, et al
    A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study.
    BMC Cancer. 2018;18:789.
    PubMed     Text format     Abstract available


  223. BAEYENS-FERNANDEZ JA, Molina-Portillo E, Pollan M, Rodriguez-Barranco M, et al
    Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
    BMC Cancer. 2018;18:781.
    PubMed     Text format     Abstract available


    July 2018
  224. VIALA M, Chiba A, Thezenas S, Delmond L, et al
    Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
    BMC Cancer. 2018;18:770.
    PubMed     Text format     Abstract available


  225. BEELEN K, Opdam M, Severson T, Koornstra R, et al
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    BMC Cancer. 2018;18:761.
    PubMed     Text format     Abstract available


  226. LEE M, Tayyari F, Pinnaduwage D, Bayani J, et al
    Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    BMC Cancer. 2018;18:750.
    PubMed     Text format     Abstract available


  227. GIBBONS JA, Kanwar JR, Kanwar RK
    Correction to: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
    BMC Cancer. 2018;18:749.
    PubMed     Text format     Abstract available


  228. RETHORST CD, Hamann HA, Carmody TJ, Sharp KJ, et al
    The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.
    BMC Cancer. 2018;18:744.
    PubMed     Text format     Abstract available


  229. VASMATZIS G, Wang X, Smadbeck JB, Murphy SJ, et al
    Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2(+) breast cancer samples.
    BMC Cancer. 2018;18:738.
    PubMed     Text format     Abstract available


  230. LAMBERT LK, Balneaves LG, Howard AF, Chia SK, et al
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    BMC Cancer. 2018;18:732.
    PubMed     Text format     Abstract available


  231. NUSHTAEVA AA, Stepanov GA, Semenov DV, Juravlev ES, et al
    Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
    BMC Cancer. 2018;18:728.
    PubMed     Text format     Abstract available


  232. HE Y, Tan EH, Wong ALA, Tan CC, et al
    Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
    BMC Cancer. 2018;18:727.
    PubMed     Text format     Abstract available


  233. YOON YN, Choe MH, Jung KY, Hwang SG, et al
    MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
    BMC Cancer. 2018;18:716.
    PubMed     Text format     Abstract available


  234. SLAOUI M, Zoure AA, Mouh FZ, Bensouda Y, et al
    Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    BMC Cancer. 2018;18:713.
    PubMed     Text format     Abstract available


  235. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Text format     Abstract available


  236. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Text format     Abstract available


    June 2018
  237. ZOPPINO FCM, Guerrero-Gimenez ME, Castro GN, Ciocca DR, et al
    Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer.
    BMC Cancer. 2018;18:700.
    PubMed     Text format     Abstract available


  238. HAYASHIDA T, Jinno H, Mori K, Sato H, et al
    Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    BMC Cancer. 2018;18:701.
    PubMed     Text format     Abstract available


  239. VAN GELDERMALSEN M, Quek LE, Turner N, Freidman N, et al
    Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
    BMC Cancer. 2018;18:689.
    PubMed     Text format     Abstract available


  240. EHLERS DK, Fanning J, Salerno EA, Aguinaga S, et al
    Replacing sedentary time with physical activity or sleep: effects on cancer-related cognitive impairment in breast cancer survivors.
    BMC Cancer. 2018;18:685.
    PubMed     Text format     Abstract available


  241. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Text format     Abstract available


  242. INOUE K, Ninomiya J, Saito T, Kimizuka K, et al
    Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 3
    BMC Cancer. 2018;18:671.
    PubMed     Text format     Abstract available


  243. LI Y, Du Y, Sun T, Xue H, et al
    PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
    BMC Cancer. 2018;18:669.
    PubMed     Text format     Abstract available


  244. LI R, Xiao C, Liu H, Huang Y, et al
    Effects of local anesthetics on breast cancer cell viability and migration.
    BMC Cancer. 2018;18:666.
    PubMed     Text format     Abstract available


  245. XU H, Xu Y, Ouyang T, Li J, et al
    Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    BMC Cancer. 2018;18:662.
    PubMed     Text format     Abstract available


  246. LOFTEROD T, Mortensen ES, Nalwoga H, Wilsgaard T, et al
    Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    BMC Cancer. 2018;18:654.
    PubMed     Text format     Abstract available


  247. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:651.
    PubMed     Text format     Abstract available


  248. DUSENGIMANA JMV, Hategekimana V, Borg R, Hedt-Gauthier B, et al
    Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of Excellence.
    BMC Cancer. 2018;18:634.
    PubMed     Text format     Abstract available


    May 2018
  249. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
    Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
    BMC Cancer. 2018;18:616.
    PubMed     Text format     Abstract available


  250. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Text format     Abstract available


  251. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Text format     Abstract available


  252. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Text format     Abstract available


  253. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Text format     Abstract available


  254. FORTE L, Turdo F, Ghirelli C, Aiello P, et al
    The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    BMC Cancer. 2018;18:586.
    PubMed     Text format     Abstract available


  255. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Text format     Abstract available


  256. PARASHAR S, Cheishvili D, Mahmood N, Arakelian A, et al
    DNA methylation signatures of breast cancer in peripheral T-cells.
    BMC Cancer. 2018;18:574.
    PubMed     Text format     Abstract available


  257. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Text format     Abstract available


  258. BANYS-PALUCHOWSKI M, Fehm T, Janni W, Aktas B, et al
    Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    BMC Cancer. 2018;18:541.
    PubMed     Text format     Abstract available


  259. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Text format     Abstract available


  260. DOUGAN MM, Li Y, Chu LW, Haile RW, et al
    Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    BMC Cancer. 2018;18:532.
    PubMed     Text format     Abstract available


  261. NAIK A, Al-Yahyaee A, Abdullah N, Sam JE, et al
    Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells.
    BMC Cancer. 2018;18:533.
    PubMed     Text format     Abstract available


  262. PENAULT-LLORCA F, Filleron T, Asselain B, Baehner FL, et al
    The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria
    BMC Cancer. 2018;18:526.
    PubMed     Text format     Abstract available


  263. LI W, Xu L, Che X, Li H, et al
    C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    BMC Cancer. 2018;18:507.
    PubMed     Text format     Abstract available


  264. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Text format     Abstract available


    April 2018
  265. HUANG S, Murphy L, Xu W
    Genes and functions from breast cancer signatures.
    BMC Cancer. 2018;18:473.
    PubMed     Text format     Abstract available


  266. FERNANDO A, Jayarajah U, Prabashani S, Fernando EA, et al
    Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database.
    BMC Cancer. 2018;18:482.
    PubMed     Text format     Abstract available


  267. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Text format     Abstract available


  268. DOGAN A, Kern P, Schultheis B, Hausler G, et al
    Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
    BMC Cancer. 2018;18:463.
    PubMed     Text format     Abstract available


  269. CATSMAN CJLM, Beek MA, Voogd AC, Mulder PGH, et al
    The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery.
    BMC Cancer. 2018;18:456.
    PubMed     Text format     Abstract available


  270. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Text format     Abstract available


  271. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Text format     Abstract available


  272. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


  273. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Text format     Abstract available


  274. XIAO B, Chen L, Ke Y, Hang J, et al
    Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    BMC Cancer. 2018;18:405.
    PubMed     Text format     Abstract available


  275. DEFOSSEZ G, Quillet A, Ingrand P
    Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    BMC Cancer. 2018;18:393.
    PubMed     Text format     Abstract available


  276. HILLER L, Dunn JA, Loi S, Vallier AL, et al
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    BMC Cancer. 2018;18:391.
    PubMed     Text format     Abstract available


  277. VAN DER WAAL D, Verbeek ALM, Broeders MJM
    Breast density and breast cancer-specific survival by detection mode.
    BMC Cancer. 2018;18:386.
    PubMed     Text format     Abstract available


  278. BALEKOUZOU A, Yin P, Bekolo CE, Pamatika CM, et al
    Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases.
    BMC Cancer. 2018;18:387.
    PubMed     Text format     Abstract available


  279. PHI XA, Tagliafico A, Houssami N, Greuter MJW, et al
    Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.
    BMC Cancer. 2018;18:380.
    PubMed     Text format     Abstract available


  280. HUNG CH, Chen FM, Lin YC, Tsai ML, et al
    Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
    BMC Cancer. 2018;18:366.
    PubMed     Text format     Abstract available


  281. LIU Y, Du Y, Hu X, Zhao L, et al
    Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
    BMC Cancer. 2018;18:367.
    PubMed     Text format     Abstract available


    March 2018
  282. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Text format     Abstract available


  283. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Text format     Abstract available


  284. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Text format     Abstract available


  285. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Text format     Abstract available


  286. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Text format     Abstract available


  287. SALIMI M, Wang R, Yao X, Li X, et al
    Activated innate lymphoid cell populations accumulate in human tumour tissues.
    BMC Cancer. 2018;18:341.
    PubMed     Text format     Abstract available


  288. MARMARA D, Marmara V, Hubbard G
    A national cross-sectional study of adherence to timely mammography use in Malta.
    BMC Cancer. 2018;18:346.
    PubMed     Text format     Abstract available


  289. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Text format     Abstract available


  290. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Text format     Abstract available


  291. MOODLEY J, Cairncross L, Naiker T, Constant D, et al
    From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study.
    BMC Cancer. 2018;18:312.
    PubMed     Text format     Abstract available


  292. ZHANG JJ, Shu H, Hu SS, Yu Y, et al
    Relationship between time elapsed since completion of radiotherapy and quality of life of patients with breast cancer.
    BMC Cancer. 2018;18:305.
    PubMed     Text format     Abstract available


  293. MENSAH KB, Oosthuizen F, Bonsu AB
    Cancer awareness among community pharmacist: a systematic review.
    BMC Cancer. 2018;18:299.
    PubMed     Text format     Abstract available


  294. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Text format     Abstract available


  295. HARDI H, Melki R, Boughaleb Z, El Harroudi T, et al
    Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    BMC Cancer. 2018;18:292.
    PubMed     Text format     Abstract available


  296. MCANENA PF, McGuire A, Ramli A, Curran C, et al
    Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:282.
    PubMed     Text format     Abstract available


  297. DAVID D, Surendran A, Thulaseedharan JV, Nair AS, et al
    Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
    BMC Cancer. 2018;18:284.
    PubMed     Text format     Abstract available


  298. DIERSSEN-SOTOS T, Palazuelos-Calderon C, Jimenez-Moleon JJ, Aragones N, et al
    Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project.
    BMC Cancer. 2018;18:280.
    PubMed     Text format     Abstract available


  299. SONG Q, Chen Q, Wang Q, Yang L, et al
    ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer.
    BMC Cancer. 2018;18:255.
    PubMed     Text format     Abstract available


  300. NAAB TJ, Gautam A, Ricks-Santi L, Esnakula AK, et al
    MYC amplification in subtypes of breast cancers in African American women.
    BMC Cancer. 2018;18:274.
    PubMed     Text format     Abstract available


  301. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Text format     Abstract available


  302. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Text format     Abstract available


  303. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Text format     Abstract available


  304. ANWAR SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, et al
    Determinants of cancer screening awareness and participation among Indonesian women.
    BMC Cancer. 2018;18:208.
    PubMed     Text format     Abstract available


  305. SANKATSING VDV, Fracheboud J, de Munck L, Broeders MJM, et al
    Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.
    BMC Cancer. 2018;18:256.
    PubMed     Text format     Abstract available


    February 2018
  306. ISFOSS BL, Holmqvist B, Sand E, Forsell J, et al
    Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    BMC Cancer. 2018;18:230.
    PubMed     Text format     Abstract available


  307. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Text format     Abstract available


  308. GAVA F, Rigal L, Mondesert O, Pesce E, et al
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells.
    BMC Cancer. 2018;18:221.
    PubMed     Text format     Abstract available


  309. JAASKELAINEN A, Soini Y, Jukkola-Vuorinen A, Auvinen P, et al
    High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    BMC Cancer. 2018;18:223.
    PubMed     Text format     Abstract available


  310. BRONSVELD HK, De Bruin ML, Wesseling J, Sanders J, et al
    The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
    BMC Cancer. 2018;18:224.
    PubMed     Text format     Abstract available


  311. HOU MF, Chen PM, Chu PY
    LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    BMC Cancer. 2018;18:219.
    PubMed     Text format     Abstract available


  312. MCANENA PF, Brown JA, Ramli A, Curran C, et al
    Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:203.
    PubMed     Text format     Abstract available


  313. HUEBNER H, Fasching PA, Gumbrecht W, Jud S, et al
    Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    BMC Cancer. 2018;18:204.
    PubMed     Text format     Abstract available


  314. WESTVIK AS, Weedon-Fekjaer H, Maehlen J, Liestol K, et al
    Evaluating different breast tumor progression models using screening data.
    BMC Cancer. 2018;18:209.
    PubMed     Text format     Abstract available


  315. SIRISENA ND, Adeyemo A, Kuruppu AI, Neththikumara N, et al
    Genetic determinants of sporadic breast cancer in Sri Lankan women.
    BMC Cancer. 2018;18:180.
    PubMed     Text format     Abstract available


  316. NOJIMA M, Iwasaki M, Kasuga Y, Yokoyama S, et al
    Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study.
    BMC Cancer. 2018;18:184.
    PubMed     Text format     Abstract available


  317. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


  318. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Text format     Abstract available


  319. KJALLQUIST U, Erlandsson R, Tobin NP, Alkodsi A, et al
    Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    BMC Cancer. 2018;18:174.
    PubMed     Text format     Abstract available


  320. AL DOSSARY R, Alkharsah KR, Kussaibi H
    Prevalence of Mouse Mammary Tumor Virus (MMTV)-like sequences in human breast cancer tissues and adjacent normal breast tissues in Saudi Arabia.
    BMC Cancer. 2018;18:170.
    PubMed     Text format     Abstract available


  321. LAFOURCADE A, His M, Baglietto L, Boutron-Ruault MC, et al
    Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
    BMC Cancer. 2018;18:171.
    PubMed     Text format     Abstract available


  322. NGUYEN-DUMONT T, Teo ZL, Hammet F, Roberge A, et al
    Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
    BMC Cancer. 2018;18:165.
    PubMed     Text format     Abstract available


  323. CORTET M, Bertaut A, Molinie F, Bara S, et al
    Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
    BMC Cancer. 2018;18:161.
    PubMed     Text format     Abstract available


  324. LAM WWT, Kwong A, Suen D, Tsang J, et al
    Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study.
    BMC Cancer. 2018;18:162.
    PubMed     Text format     Abstract available


  325. LIM JA, Oh CS, Yoon TG, Lee JY, et al
    The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.
    BMC Cancer. 2018;18:159.
    PubMed     Text format     Abstract available


  326. ABDEL-RAZEQ H, Al-Omari A, Zahran F, Arun B, et al
    Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    BMC Cancer. 2018;18:152.
    PubMed     Text format     Abstract available


  327. PENSABENE M, Stanzione B, Cerillo I, Ciancia G, et al
    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
    BMC Cancer. 2018;18:146.
    PubMed     Text format     Abstract available


  328. ALUNNI-FABBRONI M, Majunke L, Trapp EK, Tzschaschel M, et al
    Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    BMC Cancer. 2018;18:141.
    PubMed     Text format     Abstract available


  329. TRAORE BM, El Fakir S, Charaka H, Benaicha N, et al
    Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.
    BMC Cancer. 2018;18:109.
    PubMed     Text format     Abstract available


  330. NOVAK J, Besic N, Dzodic R, Gazic B, et al
    Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy.
    BMC Cancer. 2018;18:137.
    PubMed     Text format     Abstract available


  331. BEGUINOT M, Dauplat MM, Kwiatkowski F, Lebouedec G, et al
    Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    BMC Cancer. 2018;18:129.
    PubMed     Text format     Abstract available


  332. KAEWKANGSADAN V, Verma C, Eremin JM, Cowley G, et al
    Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumo
    BMC Cancer. 2018;18:123.
    PubMed     Text format     Abstract available


    January 2018
  333. EVANS RL, Pottala JV, Nagata S, Egland KA, et al
    Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
    BMC Cancer. 2018;18:119.
    PubMed     Text format     Abstract available


  334. HSIEH E, Wang Q, Zhang R, Niu X, et al
    Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.
    BMC Cancer. 2018;18:104.
    PubMed     Text format     Abstract available


  335. FRERES P, Bouznad N, Servais L, Josse C, et al
    Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:102.
    PubMed     Text format     Abstract available


  336. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


  337. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Text format     Abstract available


  338. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Text format     Abstract available


  339. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Text format     Abstract available


  340. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Text format     Abstract available


  341. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Text format     Abstract available


  342. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Text format     Abstract available


  343. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Text format     Abstract available


  344. GARCIA-GUTIERREZ S, Orive M, Sarasqueta C, Legarreta MJ, et al
    Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.
    BMC Cancer. 2018;18:54.
    PubMed     Text format     Abstract available


  345. DALL P, Koch T, Gohler T, Selbach J, et al
    Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.
    BMC Cancer. 2018;18:51.
    PubMed     Text format     Abstract available


  346. TIN TIN S, Elwood JM, Brown C, Sarfati D, et al
    Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
    BMC Cancer. 2018;18:58.
    PubMed     Text format     Abstract available


  347. URRU SAM, Gallus S, Bosetti C, Moi T, et al
    Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    BMC Cancer. 2018;18:56.
    PubMed     Text format     Abstract available


  348. KUMAR D, Haldar S, Gorain M, Kumar S, et al
    Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.
    BMC Cancer. 2018;18:52.
    PubMed     Text format     Abstract available


  349. LOVITT CJ, Shelper TB, Avery VM
    Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
    BMC Cancer. 2018;18:41.
    PubMed     Text format     Abstract available


  350. PARK E, Yoon J, Choi EK, Kim IR, et al
    A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors.
    BMC Cancer. 2018;18:45.
    PubMed     Text format     Abstract available


  351. LOUHICHI T, Saad H, Dhiab MB, Ziadi S, et al
    Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    BMC Cancer. 2018;18:49.
    PubMed     Text format     Abstract available


  352. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Text format     Abstract available


  353. NZEANGUNG BA, Biwole ME, Kadia BM, Bechem NN, et al
    Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon.
    BMC Cancer. 2018;18:32.
    PubMed     Text format     Abstract available


  354. NARRANDES S, Huang S, Murphy L, Xu W, et al
    The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    BMC Cancer. 2018;18:22.
    PubMed     Text format     Abstract available


  355. ZHOU K, He X, Huo L, An J, et al
    Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients.
    BMC Cancer. 2018;18:19.
    PubMed     Text format     Abstract available


  356. PATRICIO M, Pereira J, Crisostomo J, Matafome P, et al
    Using Resistin, glucose, age and BMI to predict the presence of breast cancer.
    BMC Cancer. 2018;18:29.
    PubMed     Text format     Abstract available


  357. LI M, Li A, Zhou S, Xu Y, et al
    Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    BMC Cancer. 2018;18:4.
    PubMed     Text format     Abstract available


    December 2017
  358. LYNGE E, Bak M, von Euler-Chelpin M, Kroman N, et al
    Outcome of breast cancer screening in Denmark.
    BMC Cancer. 2017;17:897.
    PubMed     Text format     Abstract available


  359. HUANG LH, Chung HY, Su HM
    Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    BMC Cancer. 2017;17:890.
    PubMed     Text format     Abstract available


  360. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    BMC Cancer. 2017;17:888.
    PubMed     Text format     Abstract available


  361. MERCOGLIANO MF, Inurrigarro G, De Martino M, Venturutti L, et al
    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    BMC Cancer. 2017;17:895.
    PubMed     Text format     Abstract available


  362. LIU LN, Lin YC, Miaskowski C, Chen SC, et al
    Association between changes in body fat and disease progression after breast cancer surgery is moderated by menopausal status.
    BMC Cancer. 2017;17:863.
    PubMed     Text format     Abstract available


  363. KRISHNAN K, Baglietto L, Stone J, McLean C, et al
    Mammographic density and risk of breast cancer by tumor characteristics: a case-control study.
    BMC Cancer. 2017;17:859.
    PubMed     Text format     Abstract available


  364. KUMARI K, Keshari S, Sengupta D, Sabat SC, et al
    Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
    BMC Cancer. 2017;17:858.
    PubMed     Text format     Abstract available


  365. WU Y, Zhang N, Yang Q
    The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    BMC Cancer. 2017;17:839.
    PubMed     Text format     Abstract available


  366. GAO D, Cazares LH, Fish EN
    CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    BMC Cancer. 2017;17:834.
    PubMed     Text format     Abstract available


  367. BAXTER GD, Liu L, Petrich S, Gisselman AS, et al
    Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2017;17:833.
    PubMed     Text format     Abstract available


  368. PHAM TND, Perez White BE, Zhao H, Mortazavi F, et al
    Protein kinase C alpha enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    BMC Cancer. 2017;17:832.
    PubMed     Text format     Abstract available


  369. KO H, Shin J, Lee JE, Nam SJ, et al
    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    BMC Cancer. 2017;17:821.
    PubMed     Text format     Abstract available


  370. OCHNIK AM, Baxter RC
    Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
    BMC Cancer. 2017;17:820.
    PubMed     Text format     Abstract available


  371. HE D, Fang Y, Gunter MJ, Xu D, et al
    Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.
    BMC Cancer. 2017;17:824.
    PubMed     Text format     Abstract available


  372. IIZUMI S, Shimoi T, Tsushita N, Bun S, et al
    Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    BMC Cancer. 2017;17:819.
    PubMed     Text format     Abstract available


  373. THOMAS ET, Del Mar C, Glasziou P, Wright G, et al
    Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.
    BMC Cancer. 2017;17:808.
    PubMed     Text format     Abstract available


  374. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Text format     Abstract available


    November 2017
  375. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Text format     Abstract available


  376. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Text format     Abstract available


  377. GIORDANO L, Gallo F, Petracci E, Chiorino G, et al
    The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    BMC Cancer. 2017;17:785.
    PubMed     Text format     Abstract available


  378. TAKESHITA T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, et al
    Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    BMC Cancer. 2017;17:786.
    PubMed     Text format     Abstract available


  379. WONG XY, Chong KJ, van Til JA, Wee HL, et al
    A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    BMC Cancer. 2017;17:776.
    PubMed     Text format     Abstract available


  380. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Text format     Abstract available


  381. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Text format     Abstract available


  382. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Text format     Abstract available


  383. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Text format     Abstract available


  384. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Text format     Abstract available


  385. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Text format     Abstract available


  386. MINICHILLO S, Gallelli I, Barbieri E, Cubelli M, et al
    Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
    BMC Cancer. 2017;17:722.
    PubMed     Text format     Abstract available


  387. QUINTERO M, Adamoski D, Reis LMD, Ascencao CFR, et al
    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    BMC Cancer. 2017;17:727.
    PubMed     Text format     Abstract available


  388. GOHR K, Hamacher A, Engelke LH, Kassack MU, et al
    Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC Cancer. 2017;17:711.
    PubMed     Text format     Abstract available


  389. LANZ HL, Saleh A, Kramer B, Cairns J, et al
    Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    BMC Cancer. 2017;17:709.
    PubMed     Text format     Abstract available


    October 2017
  390. REPO H, Gurvits N, Loyttyniemi E, Nykanen M, et al
    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
    BMC Cancer. 2017;17:705.
    PubMed     Text format     Abstract available


  391. D'ALOISIO AA, Nichols HB, Hodgson ME, Deming-Halverson SL, et al
    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    BMC Cancer. 2017;17:692.
    PubMed     Text format     Abstract available


  392. KIM HM, Lee J, Koo JS
    Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    BMC Cancer. 2017;17:690.
    PubMed     Text format     Abstract available


  393. JAHN B, Rochau U, Kurzthaler C, Hubalek M, et al
    Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    BMC Cancer. 2017;17:685.
    PubMed     Text format     Abstract available


  394. LYSZCZARZ B, Nojszewska E
    Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.
    BMC Cancer. 2017;17:676.
    PubMed     Text format     Abstract available


    September 2017
  395. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Text format     Abstract available


  396. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    PubMed     Text format     Abstract available


  397. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Text format     Abstract available


  398. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    PubMed     Text format     Abstract available


  399. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    PubMed     Text format     Abstract available


    May 2017
  400. VOELS B, Wang L, Sens DA, Garrett SH, et al
    The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.
    BMC Cancer. 2017;17:369.
    PubMed     Text format     Abstract available


  401. DEMOOR-GOLDSCHMIDT C, Drui D, Doutriaux I, Michel G, et al
    A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
    BMC Cancer. 2017;17:326.
    PubMed     Text format     Abstract available


  402. BOGAN D, Meile L, El Bastawisy A, Yousef HF, et al
    The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    BMC Cancer. 2017;17:329.
    PubMed     Text format     Abstract available


  403. CHIN-QUEE K, Donahue HJ
    MDA-MET-conditioned-medium augments the chemoattractant-dependent migration of MDA-MET cells towards hFOB-conditioned medium and increases collagenase activity.
    BMC Cancer. 2017;17:324.
    PubMed     Text format     Abstract available


    April 2017
  404. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Text format     Abstract available


    March 2017
  405. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: